Approved indications: Deferoxamine mesylate is approved as an adjunct to standard measures for treating acute iron intoxication and for treating transfusional iron overload in patients with chronic anemias (for example thalassemia or other transfusion‑dependent anemias); it is not indicated for primary hereditary hemochromatosis, where phlebotomy is preferred.

Off‑label uses: Clinicians also use deferoxamine to manage aluminum overload in patients on long‑term dialysis or parenteral nutrition and in some other iron overload states when standard options are unsuitable, based mostly on observational studies, case series, and expert guidelines rather than large randomized trials.

Efficacy expectations: In chronic iron overload, urinary iron excretion typically rises promptly and serum ferritin often begins to fall over several weeks, with substantial reductions in liver and cardiac iron and improved organ outcomes over months to years when infusions are given regularly and doses are optimized.

Acute poisoning efficacy: In severe acute iron intoxication, deferoxamine can lower circulating free iron within hours, and improvement in blood pressure, acidosis, and mental status often parallels this, though it is always used together with standard supportive and decontamination measures.

Comparison with other chelators: When adherence is good, deferoxamine can reduce body iron stores as effectively as oral chelators, but its need for prolonged injections or infusions makes it less convenient; it remains the treatment of choice for severe acute iron poisoning and is favored in some patients with very high iron burdens, pregnancy, or intolerance or contraindications to oral agents.

Chronic transfusional iron overload: Typical subcutaneous infusion doses are about 20–60 mg/kg/day (often 40–50 mg/kg/day in adults and 20–40 mg/kg/day in children) delivered over 8–12 hours using a portable pump on 5–7 days per week, with pediatric daily doses usually kept at or below 40 mg/kg/day until growth is complete and adult daily doses not exceeding about 60 mg/kg/day.

Acute iron intoxication: In adults and children with severe acute iron poisoning, an initial 1,000 mg dose is usually given intramuscularly or by slow intravenous infusion at a rate not exceeding about 15 mg/kg/hour, followed by additional 500 mg doses every 4–12 hours as needed, up to a total maximum of 6,000 mg in 24 hours, with therapy adjusted based on symptoms, serum iron levels, and kidney function.

How it is given: Deferoxamine comes as a powder that is mixed with sterile liquid and then administered by deep intramuscular injection, slow intravenous infusion, or most commonly by prolonged subcutaneous infusion through a small needle under the skin (often in the abdomen) using a portable pump, usually at home and often overnight; it is not taken by mouth and can be given without regard to meals.

Special dosing instructions: Doses are individualized to the degree of iron overload and tolerability, reduced or avoided in significant renal impairment, and periodically adjusted according to ferritin and other iron measures, with growth monitoring in children; low‑dose vitamin C may be added only after several weeks of regular chelation and within recommended limits to avoid cardiac complications.

Missed dose and overdose: If a scheduled infusion or injection is missed, it is generally taken as soon as remembered unless it is close to the next scheduled dose, in which case the missed dose is skipped without doubling; suspected overdose or excessively rapid infusion causing severe dizziness, shortness of breath, chest pain, confusion, or collapse requires immediate medical assessment, often with emergency care and poison‑control involvement.

Common side effects: The most frequent reactions are injection‑site pain, redness, swelling, or itching; low‑grade fever, fatigue, muscle or joint aches; mild rash; dark or reddish‑brown urine; and nausea, vomiting, or abdominal discomfort, which usually occur early in therapy or after dose increases and are often mild to moderate.

Serious or rare adverse effects: Important but less common risks include severe allergic reactions (hives, wheezing, throat swelling, collapse), marked low blood pressure and shock with rapid IV infusion, acute lung injury (acute respiratory distress syndrome) at very high IV doses, kidney injury or failure, severe infections with iron‑loving organisms such as Yersinia or Vibrio species, and retinal or optic nerve changes and high‑frequency hearing loss, particularly with prolonged high‑dose use or when iron stores are already low.

Warnings and precautions: Deferoxamine is contraindicated in patients with severe renal disease or anuria and should be used cautiously with dose reductions and close monitoring in milder kidney impairment; long‑term high doses in young children can slow growth and affect bones, so growth and body weight are checked regularly; pregnancy data are limited so it is generally reserved for situations where expected benefit clearly outweighs risk, breastfeeding is usually avoided during therapy and for a short period afterward, and extra caution is needed in older adults and in patients with pre‑existing eye, ear, heart, or lung disease.

Relative safety profile: Compared with oral iron chelators, deferoxamine has a long safety track record and predictable toxicities but causes more local injection‑site reactions and has distinctive risks such as infusion‑related hypotension and siderophilic infections, while serious organ toxicity is uncommon when recommended dose limits and monitoring are followed.

Side‑effect reporting and safety updates: Suspected adverse effects should be reported to the FDA’s MedWatch program or to the product manufacturer, and clinicians can consult current FDA safety communications and the latest prescribing information for updated warnings, contraindications, and monitoring recommendations.

Drug and supplement interactions: High‑dose vitamin C can worsen cardiac dysfunction in heavily iron‑overloaded patients on deferoxamine, so vitamin C is typically limited to modest doses and started only after several weeks of chelation; concurrent use with prochlorperazine has been associated with episodes of transient loss of consciousness; and extra caution is advised when combining deferoxamine with other nephrotoxic drugs (such as some antibiotics or NSAIDs) or agents that can damage hearing or vision (for example aminoglycosides or high‑dose loop diuretics) because toxic effects may be additive.

Food, alcohol, and diagnostic procedures: No specific food interactions are known, and while alcohol has no direct interaction, it may compound liver or heart stress in patients with iron overload; deferoxamine can chelate radiotracers and interfere with gallium‑67 and some other metal‑based nuclear‑medicine scans, so imaging teams should be informed about current or recent therapy and may need to adjust timing of studies.

Conditions and co‑medications requiring caution: Use may be unsafe or require dose reduction in severe kidney impairment, very low baseline iron stores, active serious infections (especially with Yersinia or Vibrio species), significant heart or lung disease, or pre‑existing eye or ear disorders, and young children need particularly careful monitoring of growth and skeletal development.

Monitoring needs: During treatment, clinicians usually monitor complete blood counts, serum ferritin and other iron studies, kidney and liver function, and in long‑term use periodic eye examinations, hearing tests, and in children growth and body‑proportion measurements; in higher‑risk patients, cardiac imaging or function tests may also be obtained to track iron‑related heart disease.

Q: What conditions is deferoxamine mesylate used to treat?
A: It is mainly used to treat acute iron poisoning and to remove excess iron that accumulates in people who receive many blood transfusions for chronic anemias.

Q: How long will I need to stay on deferoxamine for iron overload?
A: Most people with transfusional iron overload require long‑term treatment for as long as they continue to receive regular transfusions, with dose and schedule adjusted over time based on iron levels and organ function.

Q: Why is deferoxamine usually given by a pump under the skin instead of as quick injections?
A: Slow subcutaneous infusion over many hours allows effective iron chelation with fewer side effects, while rapid injections or infusions increase the risk of pain, low blood pressure, and other reactions.

Q: My urine turns reddish‑brown when I use deferoxamine—should I be worried?
A: Dark or reddish‑brown urine is common with this medicine and usually reflects the iron–deferoxamine complex being excreted, but sudden changes in urine output, swelling, or other symptoms should be reported to your clinician to rule out kidney problems.

Q: Can I switch from deferoxamine injections to an oral iron chelator?
A: Many patients can transition to or combine treatment with an oral chelator, but the choice depends on your iron burden, other medical conditions, pregnancy plans, and previous side effects, so any change should be planned with your specialist.

Q: Is deferoxamine safe during pregnancy or breastfeeding?
A: Because human data are limited, deferoxamine is usually reserved in pregnancy for women with severe iron overload when the benefits are judged to outweigh potential risks, and breastfeeding is generally avoided during treatment and for a short time after the last dose.

Storage: Store unmixed vials at room temperature (about 68–77°F / 20–25°C) in the original carton, protected from heat, moisture, and light, and keep all vials out of the reach of children and pets.

After mixing: Use the reconstituted solution promptly; if it must be stored, keep it at room temperature for only the time specified by your pharmacist or infusion service (often no more than about 24 hours), and do not refrigerate or freeze mixed solution.

Disposal: Discard any unused mixed solution, used vials, needles, and tubing in the sharps or biohazard containers provided, and take expired or unwanted vials to a pharmacy or community drug take‑back program rather than throwing them in household trash or flushing them down the toilet.